Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 11/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.31 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12180125 | 0.86 | GOT1 (0.39) | GOT1PHGDHHPGDSGAABRD4 | |
| SCHEMBL12286232 | 0.85 | GPR52 (0.33) | GOT1PHGDHGAAMEN1KMT2A | |
| SCHEMBL806552 | 0.84 | GAA (0.34) | GOT1PHGDHHPGDSGAABRD4 | |
| SCHEMBL14933295 | 0.84 | BRD4 (0.38) | GOT1PHGDHHPGDSGAABRD4 | |
| SCHEMBL12287242 | 0.81 | EZH2 (0.33) | — | |
| SCHEMBL13983476 | 0.77 | HSP90AA1 (0.53) | — | |
| SCHEMBL9925250 | 0.76 | GOT1 (0.36) | GOT1HPGDSGAABRD4BRD2 | |
| SCHEMBL806553 | 0.76 | HSP90AA1 (0.40) | GOT1HPGDSGAAMAPTDHFR | |
| SCHEMBL13983147 | 0.76 | HSP90AA1 (0.43) | GAAALDH1A1MAPTKMT2A | |
| SCHEMBL14342348 | 0.76 | GOT1 (0.39) | GOT1PHGDHGAAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013170159-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013074594-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH BRAF INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013067162-A1 | CANCER THERAPY USING A COMBINATION OF HSP90 INHIBITORS WITH TOPOISOMERASE I INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2012162584-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012037072-A1 | HSP90 INHIBITORS FOR TREATING NON-SMALL CELL LUNG CANCERS IN WILD-TYPE EGFR AND/OR KRAS PATIENTS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011149824-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011146803-A1 | METHOD OF TREATING LUNG ADENOCARCINOMA WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-24 | — | — | WO | disclosed |